The Red Cell Distribution Width/Albumin Ratio in STEMI: Biologically Plausible but Clinically Unproven

We read with great interest the article by Li et al, “Red Cell Distribution Width/Albumin Ratio as a Valuable Marker to Predict Spontaneous Recanalization in Acute ST-Segment Elevation Myocardial Infarction”. ¹ The authors are to be commended for exploring a simple, widely available, and inexpensive composite biomarker to improve early risk stratification in patients with ST-segment elevation myocardial infarction (STEMI). The investigation of the red cell distribution width-to-albumin ratio (RAR) is grounded in sound pathophysiology: combining a marker of inflammation and anisocytosis (red cell distribution width) with a negative acute-phase reactant reflecting nutritional and antioxidant status (albumin) represents a logical approach to capturing the systemic stress state.^1,2 Indeed, albumin serves as a central “hub” for numerous prognostic indices in cardiovascular medicine. There is significant overlap between established tools such as the Prognostic Nutritional Index (PNI), the Controlling Nutritional Status (CONUT) score, and the Geriatric Nutritional Risk Index (GNRI). ² All these indices rely on albumin not merely as a nutritional marker, but as a surrogate for systemic inflammation, endothelial dysfunction, and oxidative stress burden in patients with acute coronary syndromes.

However, while Li et al report a statistically significant association between higher RAR and absence of spontaneous recanalization (adjusted odds ratio = 2.528, 95% CI: 1.019-6.276), we believe their conclusion that RAR is a “promising biomarker” capable of “identifying high-risk populations” for intervention represents a significant overstatement unsupported by their own predictive accuracy data. ¹ The central issue lies in the biomarker's discriminatory capacity, best assessed by the area under the receiver operating characteristic curve (AUC). The reported AUC for RAR in predicting non-spontaneous recanalization was only 0.613 (95% CI: 0.552-0.675). The AUC measures a test's ability to distinguish between two groups, where 0.5 represents no discrimination (equivalent to chance) and 1.0 represents perfect discrimination. According to established guidelines for interpreting diagnostic accuracy, AUC values between 0.6 and 0.7 are considered “poor,” and values below 0.8 generally have limited clinical utility, regardless of statistical significance. A predictive tool with such low discriminatory power would lead to unacceptably high misclassification rates in clinical practice, rendering it unsuitable for guiding critical early interventions in STEMI. Furthermore, the study evaluates RAR in isolation. ¹ For a new biomarker to be considered promising, it must demonstrate incremental value over existing, readily available tools.^2–6 The field is replete with simple inflammatory indices, such as the neutrophil-to-lymphocyte ratio (NLR) and the Systemic Immune-Inflammation Index (SII), which have demonstrated superior predictive accuracy (AUC ∼0.874) in similar cohorts. ⁴ Moreover, the prognostic value of albumin is often context-dependent. In elderly or multimorbid populations, for instance, outcomes are driven by a complex interplay of systemic factors and cardiac mechanics. Recent evidence in octogenarians suggests that albumin levels must be interpreted alongside cardiac variables–such as ejection fraction and conduction intervals (eg, paced QRS duration)–to accurately predict adverse outcomes like atrial fibrillation and mortality. ⁵

In conclusion, while Li et al provide a biologically plausible hypothesis, the evidence presented is insufficient to support RAR as a clinically valuable marker. ¹ The study's retrospective, single-center design further limits generalizability. Future research should focus on validating these results in large, prospective, multicenter cohorts and must include direct comparative analyses of RAR against other inflammatory indices to determine whether it offers incremental prognostic information. RAR is likely to provide utility only as a component within a multi-marker model that accounts for the interaction between nutritional status and cardiac function. Until such rigorous evidence becomes available, enthusiasm for the clinical application of RAR in STEMI should be tempered with appropriate caution.